The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD
- 1 August 2010
- journal article
- review article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 23 (4) , 257-267
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- Sanofi
This publication has 77 references indexed in Scilit:
- QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax, 2010
- Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2009
- Novel long‐acting bronchodilators for COPD and asthmaBritish Journal of Pharmacology, 2008
- Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPDThorax, 2008
- Cholinergic Pathways in the Lungs and Anticholinergic Therapy for Chronic Obstructive Pulmonary DiseaseProceedings of the American Thoracic Society, 2005
- Long-acting β2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?Current Opinion in Pharmacology, 2003
- Effects of Procaterol, a Beta-2-Adrenoceptor Stimulant, on Neuroeffector Transmission in Human Bronchial TissueRespiration, 1991
- A Comparison of the Bronchodilating Effects of a Beta-2 Adrenergic Agent (Albuterol) and an Anticholinergic Agent (Ipratropium Bromide), Given by Aerosol Alone or in SequenceNew England Journal of Medicine, 1986
- Ultrastructural studies on the neuromuscular control of human tracheal and bronchial muscleRespiration Physiology, 1986
- CIrcadian rhythms in lung resistance and dynamic lung compliance of healthy children. Effects of two bronchodilatorsRespiration Physiology, 1977